Science Daily

Scientists turn “junk DNA” into a powerful weapon against cancer

King’s College London researchers discovered that parts of our DNA once thought to be “junk” can actually help destroy cancer ...
Crain's Chicago Business

AbbVie cancer drug misses the mark in trial for new use

The AbbVie-Roche cancer drug venetoclax failed to meet its primary endpoint in a phase 3 trial to treat newly diagnosed higher-risk myelodysplastic syndrome, a form of blood cancer known as MDS, ...

Geron Corporation: Geron Announces Positive CHMP Opinion for RYTELO (imetelstat) for the Treatment of Adults with Transfusion-Dependent Anemia due to Lower-Risk MDS

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that the Committee for Medicinal Products ...
Australian Associated Press

Ofirnoflast (HT-6184) Receives Orphan Drug Designation from U.S. FDA for Myelodysplastic Syndromes

List, MD, member of Halia Therapeutics' Scientific Advisory Board and former President and CEO of Moffitt Cancer Center. "Ofirnoflast's approach is distinctive in that it seeks to modulate the ...